ABSTRACT

Recently gold based metallodrugs with +1 and +3 oxidation states show the significant role in the progress of medicinal chemistry, especially in the treatment of cancer, HIV virus, SARS-CoV-2 virus and other diseases. Particularly, gold(III) compounds are of the extreme attention because of their structural similarity with cisplatin, one of the first metallodrugs to be widely used for cancer treatment. A large variety of anticancer gold(III) organometallics of various families are reported in literature that have significant antiproliferative properties in vitro against selected human tumor cell lines and majority of them are also capable to overcome cisplatin resistance. The nature of inert and labile ligands plays a vital role in the anticancer activity of these compounds. The primary goal of this review is to summarize the chemistry and activity of some novel mononuclear anticancer gold(III) organometallic compounds that making themselves promising candidates for further pharmacological evaluation. The general outlooks on the progress of these compounds as clinically efficient anticancer drugs are discussed here on the basis of the available experimental evidence. Keywords: Gold(III) ion; Variety of ligands; Mononuclear organometallic compounds; Chemistry; and Anticancer activity
Publication date: 01/08/2022

https://ijbpas.com/pdf/2022/August/MS_IJBPAS_2022_6294.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.8.6294